CLEUSIMENE FRANCOIS: Open Payments
NPI 1902369713 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$670 in 28 payments from 11 companies in 2025. Trend: 2023 $29 · 2024 $526 · 2025 $670
Food & beverage: $670
| Company | Payments | Amount |
|---|---|---|
| Tris Pharma Inc | 6 | $133 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $130 |
| ABBVIE INC. | 3 | $86 |
| PFIZER INC. | 2 | $69 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Exact Sciences Corporation | 2 | $43 |
| Corcept Therapeutics | 2 | $41 |
| Novo Nordisk Inc | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
Products named: Dyanavel XR, Kerendia, ELIQUIS, QULIPTA, KEVEYIS, Korlym, UBRELVY, Ozempic.
Industry payments across FL — which companies pay providers there.
